The EDGE

Exploiting inhibitor of apoptosis proteins as therapeutic targets in hematological malignancies

S Fulda

Leukemia 2012 26: 1155-1165; advance online publication, January 9, 2012; 10.1038/leu.2012.4

Review

Pivotal role of paracrine effects in stem cell therapies in regenerative medicine: can we translate stem cell-secreted paracrine factors and microvesicles into better therapeutic strategies?

M Z Ratajczak, M Kucia, T Jadczyk, N J Greco, W Wojakowski, M Tendera and J Ratajczak

Leukemia 2012 26: 1166-1173; advance online publication, December 19, 2011; 10.1038/leu.2011.389

Concise Review

Protein kinase CK2 in hematologic malignancies: reliance on a pivotal cell survival regulator by oncogenic signaling pathways

F Piazza, S Manni, M Ruzzene, L A Pinna, C Gurrieri and G Semenzato

Leukemia 2012 26: 1174-1179; advance online publication, January 13, 2012; 10.1038/leu.2011.385

Original Articles

MOLECULAR TARGETS FOR THERAPY

Src inhibitors, PP2 and dasatinib, increase retinoic acid-induced association of Lyn and c-Raf (S259) and enhance MAPK-dependent differentiation of myeloid leukemia cells

J Congleton, R MacDonald and A Yen

Leukemia 2012 26: 1180-1188; advance online publication, December 19, 2011; 10.1038/leu.2011.390

THERAPY

Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results

P D le Coutre, F J Giles, A Hochhaus, J F Apperley, G J Ossenkoppele, R Blakesley, Y Shou, N J Gallagher, M Baccarani, J Cortes and H M Kantarjian

Leukemia 2012 26: 1189-1194; advance online publication, November 11, 2011; 10.1038/leu.2011.323

ACUTE LEUKEMIAS

The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia

L Willems, N Chapuis, A Puissant, T T Maciel, A S Green, N Jacque, C Vignon, S Park, S Guichard, O Herault, A Fricot, O Hermine, I C Moura, P Auberger, N Ifrah, F Dreyfus, D Bonnet, C Lacombe, P Mayeux, D Bouscary and J Tamburini

Leukemia 2012 26: 1195-1202; advance online publication, December 6, 2011; 10.1038/leu.2011.339

Polymorphisms in the TLR6 gene associated with the inverse association between childhood acute lymphoblastic leukemia and atopic disease

K G E Miedema, W J E Tissing, E M te Poele, W A Kamps, B Z Alizadeh, M Kerkhof, J C de Jongste, H A Smit, A P de Pagter, M Bierings, H M Boezen, D S Postma, E S J M de Bont and G H Koppelman

Leukemia 2012 26: 1203-1210; advance online publication, December 2, 2011; 10.1038/leu.2011.341

Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT

A Spyridonidis, M Labopin, C Schmid, L Volin, I Yakoub-Agha, M Stadler, N Milpied, G Socie, P Browne, S Lenhoff, M A Sanz, M Aljurf, M Mohty and V Rocha on behalf of the Immunotherapy Subcommittee of Acute Leukemia Working Party of European Blood and Marrow Transplant Group

Leukemia 2012 26: 1211-1217; advance online publication, January 31, 2012; 10.1038/leu.2011.351

Digital gene expression profiling of primary acute lymphoblastic leukemia cells

J Nordlund, A Kiialainen, O Karlberg, E C Berglund, H Göransson-Kultima, M Sønderkær, K L Nielsen, M G Gustafsson, M Behrendtz, E Forestier, M Perkkiö, S Söderhäll, G Lönnerholm and A-C Syvänen

Leukemia 2012 26: 1218-1227; advance online publication, December 16, 2011; 10.1038/leu.2011.358

Generation, selection and preclinical characterization of an Fc-optimized FLT3 antibody for the treatment of myeloid leukemia

M Hofmann, L Große-Hovest, T Nübling, E Pyż, M L Bamberg, S Aulwurm, H-J Bühring, K Schwartz, S P Haen, K Schilbach, H-G Rammensee, H R Salih and G Jung

Leukemia 2012 26: 1228-1237; advance online publication, January 6, 2012; 10.1038/leu.2011.372

Clinical significance of CADM1/TSLC1/IgSF4 expression in adult T-cell leukemia/lymphoma

S Nakahata, Y Saito, K Marutsuka, T Hidaka, K Maeda, K Hatakeyama, T Shiraga, A Goto, N Takamatsu, Y Asada, A Utsunomiya, A Okayama, Y Kubuki, K Shimoda, Y Ukai, G Kurosawa and K Morishita

Leukemia 2012 26: 1238-1246; advance online publication, January 6, 2012; 10.1038/leu.2011.379

Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association

A Renneville, N Boissel, O Nibourel, C Berthon, N Helevaut, C Gardin, J-M Cayuela, S Hayette, O Reman, N Contentin, D Bordessoule, C Pautas, S de Botton, T de Revel, C Terre, P Fenaux, X Thomas, S Castaigne, H Dombret and C Preudhomme

Leukemia 2012 26: 1247-1254; advance online publication, January 13, 2012; 10.1038/leu.2011.382

Elevated S100A8/S100A9 expression causes glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia

J A P Spijkers-Hagelstein, P Schneider, E Hulleman, J de Boer, O Williams, R Pieters and R W Stam

Leukemia 2012 26: 1255-1265; advance online publication, January 27, 2012; 10.1038/leu.2011.388

Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia

C C Porter, J Kim, S Fosmire, C M Gearheart, A van Linden, D Baturin, V Zaberezhnyy, P R Patel, D Gao, A C Tan and J DeGregori

Leukemia 2012 26: 1266-1276; advance online publication, January 13, 2012; 10.1038/leu.2011.392

GSK3 is a regulator of RAR-mediated differentiation

K Gupta, F Gulen, L Sun, R Aguilera, A Chakrabarti, J Kiselar, M K Agarwal and D N Wald

Leukemia 2012 26: 1277-1285; advance online publication, January 6, 2012; 10.1038/leu.2012.2

MYELODYSPLASIAS

Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study

U Germing, M Lauseker, B Hildebrandt, A Symeonidis, J Cermak, P Fenaux, C Kelaidi, M Pfeilstöcker, T Nösslinger, M Sekeres, J Maciejewski, D Haase, J Schanz, J Seymour, M Kenealy, R Weide, M Lübbert, U Platzbecker, P Valent, K Götze, R Stauder, S Blum, K-A Kreuzer, R Schlenk, A Ganser, W-K Hofmann, C Aul, O Krieger, A Kündgen, R Haas, J Hasford and A Giagounidis

Leukemia 2012 26: 1286-1292; advance online publication, January 13, 2012; 10.1038/leu.2011.391

CHRONIC LYMPHOCYTIC LEUKEMIA

Dysregulation of TNFα-induced necroptotic signaling in chronic lymphocytic leukemia: suppression of CYLD gene by LEF1

P Liu, B Xu, W Shen, H Zhu, W Wu, Y Fu, H Chen, H Dong, Y Zhu, K Miao, W Xu and J Li

Leukemia 2012 26: 1293-1300; advance online publication, December 13, 2011; 10.1038/leu.2011.357

The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells

A Zucchetto, T Vaisitti, D Benedetti, E Tissino, V Bertagnolo, D Rossi, R Bomben, M Dal Bo, M I Del Principe, A Gorgone, G Pozzato, G Gaidano, G Del Poeta, F Malavasi, S Deaglio and V Gattei

Leukemia 2012 26: 1301-1312; advance online publication, January 6, 2012; 10.1038/leu.2011.369

STEM CELLS

The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse

C Bachas, G J Schuurhuis, Y G Assaraf, Z J Kwidama, A Kelder, F Wouters, A N Snel, G J L Kaspers and J Cloos

Leukemia 2012 26: 1313-1320; advance online publication, January 13, 2012; 10.1038/leu.2011.383

SENSITIVITY AND RESISTANCE TO THERAPY

Omacetaxine mepesuccinate prevents cytokine-dependent resistance to nilotinib in vitro: potential role of the common β-subunit c of cytokine receptors

T Klag, N Härtel, P Erben, J Schwaab, U Schnetzke, T Schenk, A Hochhaus and P La Rosée

Leukemia 2012 26: 1321-1328; advance online publication, January 13, 2012; 10.1038/leu.2011.380

ONCOGENES, FUSION GENES AND TUMOR SUPPRESSOR GENES

Chromatin modifications induced by the AML1-ETO fusion protein reversibly silence its genomic targets through AML1 and Sp1 binding motifs

A Maiques-Diaz, F S Chou, M Wunderlich, G Gómez-López, F V Jacinto, S Rodriguez-Perales, M J Larrayoz, M J Calasanz, J C Mulloy, J C Cigudosa and S Alvarez

Leukemia 2012 26: 1329-1337; advance online publication, January 13, 2012; 10.1038/leu.2011.376

TRANSCRIPTIONAL CONTROL AND SIGNAL TRANSDUCTION

Direct interaction of PU.1 with oncogenic transcription factors reduces its serine phosphorylation and promoter binding

A Seshire, T Rößiger, M Frech, S Beez, H Hagemeyer and E Puccetti

Leukemia 2012 26: 1338-1347; advance online publication, November 22, 2011; 10.1038/leu.2011.331

APOPTOSIS

Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells

A H Daneshmanesh, M Hojjat-Farsangi, A S Khan, M Jeddi-Tehrani, M M Akhondi, A A Bayat, R Ghods, A-R Mahmoudi, R Hadavi, A Österborg, F Shokri, H Rabbani and H Mellstedt

Leukemia 2012 26: 1348-1355; advance online publication, January 6, 2012; 10.1038/leu.2011.362

LYMPHOMA

Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy

M Gupta, J J Han, M Stenson, L Wellik and T E Witzig

Leukemia 2012 26: 1356-1364; advance online publication, November 25, 2011; 10.1038/leu.2011.340

Complementary IL-23 and IL-27 anti-tumor activities cause strong inhibition of human follicular and diffuse large B-cell lymphoma growth in vivo

C Cocco, E Di Carlo, S Zupo, S Canale, A Zorzoli, D Ribatti, F Morandi, E Ognio and I Airoldi

Leukemia 2012 26: 1365-1374; advance online publication, December 23, 2011; 10.1038/leu.2011.363

Consequences of heat shock protein 72 (Hsp72) expression and activity on stress-induced apoptosis in CD30⁺ NPM–ALK⁺ anaplastic large-cell lymphomas

P Bonvini, E Zorzi, L Mussolin, M Pillon, C Romualdi, M Peron, E S G d'Amore, L Lamant and A Rosolen

Leukemia 2012 26: 1375-1382; advance online publication, January 6, 2012; 10.1038/leu.2011.367

BCL2 mutations in diffuse large B-cell lymphoma

J M Schuetz, N A Johnson, R D Morin, D W Scott, K Tan, S Ben-Nierah, M Boyle, G W Slack, M A Marra, J M Connors, A R Brooks-Wilson and R D Gascoyne

Leukemia 2012 26: 1383-1390; advance online publication, December 22, 2011; 10.1038/leu.2011.378

MYELOMA

Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation

N Giuliani, M Ferretti, M Bolzoni, P Storti, M Lazzaretti, B Dalla Palma, S Bonomini, E Martella, L Agnelli, A Neri, F Ceccarelli and C Palumbo

Leukemia 2012 26: 1391-1401; advance online publication, January 6, 2012; 10.1038/leu.2011.381

Letters to the Editor

Dll1/Notch activation accelerates multiple myeloma disease development by promoting CD138+ MM-cell proliferation

D Xu, J Hu, S Xu, E De Bruyne, E Menu, B Van Camp, K Vanderkerken and E Van Valckenborgh

Leukemia 2012 26: 1402-1405; advance online publication, November 18, 2011; 10.1038/leu.2011.332

Differential distribution of CCDC26 glioma-risk alleles in myeloid malignancies with mutant IDH1 compared with their IDH2R140-mutated or IDH-unmutated counterparts

T L Lasho, A Tefferi, A Pardanani, C M Finke, S R Fink, A A Caron, P A Decker and R B Jenkins

Leukemia 2012 26: 1406-1407; advance online publication, November 25, 2011; 10.1038/leu.2011.336

Dual inhibition of Jak2 and STAT5 enhances killing of myeloproliferative neoplasia cells

M Bar-Natan, E A Nelson, S R Walker, Y Kuang, R J Distel and D A Frank

Leukemia 2012 26: 1407-1410; advance online publication, December 2, 2011; 10.1038/leu.2011.338

Long-term WT1 peptide vaccination for patients with acute myeloid leukemia with minimal residual disease

A Tsuboi, Y Oka, T Kyo, Y Katayama, O A Elisseeva, M Kawakami, S Nishida, S Morimoto, A Murao, H Nakajima, N Hosen, Y Oji and H Sugiyama

Leukemia 2012 26: 1410-1413; advance online publication, December 13, 2011; 10.1038/leu.2011.343

Highly sensitive MRD tests for ALL based on the IKZF1 Δ3–6 microdeletion

N C Venn, V H J van der Velden, M de Bie, E Waanders, J E Giles, T Law, R P Kuiper, V de Haas, C G Mullighan, M Haber, G M Marshall, Norris MD, J J M van Dongen and R Sutton

Leukemia 2012 26: 1414-1416; advance online publication, December 9, 2011; 10.1038/leu.2011.348

Prognostic factors for acute myeloid leukemia patients with t(6;9)(p23;q34) who underwent an allogeneic hematopoietic stem cell transplant

K Ishiyama, A Takami, Y Kanda, S Nakao, M Hidaka, T Maeda, T Naoe, S Taniguchi, K Kawa, T Nagamura, K Tabuchi, Y Atsuta and H Sakamaki

Leukemia 2012 26: 1416-1419; advance online publication, December 9, 2011; 10.1038/leu.2011.350

Polymorphisms in xenobiotic transporters ABCB1, ABCG2, ABCC2, ABCC1, ABCC3 and multiple myeloma risk: a case–control study in the context of the International Multiple Myeloma rESEarch (IMMEnSE) consortium

A Martino, D Campa, G Buda, J Sainz, R García-Sanz, K Jamroziak, R M Reis, N Weinhold, M Jurado, R Ríos, Z Szemraj-Rogucka, H Marques, J Szemraj, A Stein, R Kumar, E Orciuolo, F Gemignani, S Landi, H Goldschmidt, M Petrini, C Dumontet, F Canzian and A M Rossi

Leukemia 2012 26: 1419-1422; advance online publication, December 20, 2011; 10.1038/leu.2011.352

Mast-cell leukemia exome sequencing reveals a mutation in the IgE mast-cell receptor β chain and KIT V654A

M S Spector, I Iossifov, A Kritharis, C He, J E Kolitz, S W Lowe and S L Allen

Leukemia 2012 26: 1422-1425; advance online publication, December 16, 2011; 10.1038/leu.2011.354

Reversal of T-cell tolerance in myelodysplastic syndrome through lenalidomide immune modulation

J M McDaniel, J X Zou, W Fulp, D-T Chen, A F List and P K Epling-Burnette

Leukemia 2012 26: 1425-1429; advance online publication, December 23, 2011; 10.1038/leu.2011.359

Sorafenib targets BCR kinases and blocks migratory and microenvironmental survival signals in CLL cells

M López-Guerra, S Xargay-Torrent, P Pérez-Galán, I Saborit-Villarroya, L Rosich, N Villamor, M Aymerich, G Roué, E Campo, E Montserrat and D Colomer

Leukemia 2012 26: 1429-1432; advance online publication, December 20, 2011; 10.1038/leu.2011.364

Histone deacetylase inhibitors are unable to synergize with ABT-737 in killing primary chronic lymphocytic leukaemia cells in vitro

R Ralli, K M Banks, A P Wiegmans, D Carney, J F Seymour, R W Johnstone and A E Alsop

Leukemia 2012 26: 1433-1435; advance online publication, January 6, 2012; 10.1038/leu.2011.370

Tumor-initiating capacity of CD138− and CD138+ tumor cells in the 5T33 multiple myeloma model

E Van Valckenborgh, W Matsui, P Agarwal, S Lub, X Dehui, E De Bruyne, E Menu, C Empsen, L van Grunsven, J Agarwal, Q Wang, H Jernberg-Wiklund and K Vanderkerken

Leukemia 2012 26: 1436-1439; advance online publication, January 6, 2012; 10.1038/leu.2011.373

Leukemia risk models in primary myelofibrosis: an International Working Group study

A Tefferi, A Pardanani, N Gangat, K H Begna, C A Hanson, D L Van Dyke, D Caramazza, A M Vannucchi, E Morra, M Cazzola, A Pereira, F Cervantes and F Passamonti

Leukemia 2012 26: 1439-1441; advance online publication, January 13, 2012; 10.1038/leu.2011.374

Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features

J A Woyach, G Lozanski, A S Ruppert, A Lozanski, K A Blum, J A Jones, J M Flynn, A J Johnson, M R Grever, N A Heerema and J C Byrd

Leukemia 2012 26: 1442-1444; advance online publication, January 13, 2012; 10.1038/leu.2011.375

Flt3-ITD mutations in a mouse model of radiation-induced acute myeloid leukaemia

R Finnon, N Brown, J Moody, C Badie, C-H Olme, R Huiskamp, E Meijne, M Sutmuller, M Rosemann and S D Bouffler

Leukemia 2012 26: 1445-1446; advance online publication, January 6, 2012; 10.1038/leu.2011.377

Unraveling the role of FANCD2 in chronic myeloid leukemia

A Valeri, P Río, X Agirre, F Prosper and J A Bueren

Leukemia 2012 26: 1447-1448; advance online publication, February 6, 2012; 10.1038/leu.2012.32